GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (FRA:3O8) » Definitions » Other Gross PPE

Omeros (FRA:3O8) Other Gross PPE : €9.59 Mil (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Omeros Other Gross PPE?

Omeros's Other Gross PPE for the quarter that ended in Dec. 2023 was €9.59 Mil.

Omeros's quarterly Other Gross PPE declined from Jun. 2023 (€27.80 Mil) to Sep. 2023 (€27.62 Mil) and declined from Sep. 2023 (€27.62 Mil) to Dec. 2023 (€9.59 Mil).

Omeros's annual Other Gross PPE increased from Dec. 2021 (€8.03 Mil) to Dec. 2022 (€8.82 Mil) and increased from Dec. 2022 (€8.82 Mil) to Dec. 2023 (€9.59 Mil).


Omeros Other Gross PPE Historical Data

The historical data trend for Omeros's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Omeros Other Gross PPE Chart

Omeros Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.49 7.06 8.03 8.82 9.59

Omeros Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.82 28.18 27.80 27.62 9.59

Omeros Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.


Omeros (FRA:3O8) Business Description

Traded in Other Exchanges
Address
201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Omeros (FRA:3O8) Headlines

No Headlines